Beyond BioNTech and Moderna, will CureVac be the future leader in mRNA vaccines?

SOPHIA-ANTIPOLIS, France – February 01, 2021 | After three decades of research, mRNA-based vaccines have proven their safety and efficacy. They have finally reached the market, holding the promise to revolutionize the field. In December 2020, the FDA and EMA granted historic authorization to the first mRNA vaccine in the United States and in Europe.[…]

Biofidelity, the UK start-up about to revolutionise amplification-based cancer diagnostics

SOPHIA-ANTIPOLIS, France – August 31, 2020 | Biofidelity recently announced that it has raised $12 million, completing its Series A financing. The company disclosed that the series A investors are BlueYard Capital, Longwall Ventures and Agilent Technologies. Biofidelity is, above all, focused on developing non-small cell lung cancer detection assays that surpass the performance of[…]

Microneedle patch in the race for COVID-19 vaccine

SOPHIA-ANTIPOLIS, France – August 24, 2020 | The race to find a COVID-19 vaccine has highlighted several microneedle technologies for their advantages over common parenteral injections. Microneedles have shown immense potential, since they can efficiently, painlessly and safely deliver a vaccine through the skin. Microneedles reach the underlying dermis and epidermis, rich in antigen presenting[…]

COVID-19 markers test using a microfluidics technology developed by Optofluidic Bioassay

SOPHIA-ANTIPOLIS, France – April 28, 2020 | According to Optofluidic Bioassay, COVID-19 antibody testing which is portable, fast, cheap and highly precise could be possible with a microfluidic device invented by the company. Optofluidic Bioassay was founded in 2015 as a spin-off of the University of Michigan. The company was identified as relevant microfluidics company[…]